Vaxxinity Valuation
| VAXXDelisted Stock | USD 2.72 0.19 6.53% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Vaxxinity has a current Real Value of $2.17 per share. The regular price of the company is $2.72. Our model measures the value of Vaxxinity from inspecting the company fundamentals such as Return On Equity of -1.51, shares owned by institutions of 12.24 %, and Shares Outstanding of 112.91 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vaxxinity's price fluctuation is very steady at this time. Calculation of the real value of Vaxxinity is based on 3 months time horizon. Increasing Vaxxinity's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vaxxinity is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vaxxinity Pink Sheet. However, Vaxxinity's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.72 | Real 2.17 | Hype 2.72 | Naive 3.01 |
The intrinsic value of Vaxxinity's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxxinity's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxxinity helps investors to forecast how Vaxxinity pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxxinity more accurately as focusing exclusively on Vaxxinity's fundamentals will not take into account other important factors: Vaxxinity Total Value Analysis
Vaxxinity is at this time anticipated to have valuation of (1.39 M) with market capitalization of 14.09 M, debt of 15.17 M, and cash on hands of 128.23 M. The negative valuation of Vaxxinity may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Vaxxinity fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.39 M) | 14.09 M | 15.17 M | 128.23 M |
Vaxxinity Asset Utilization
One of the ways to look at asset utilization of Vaxxinity is to check how much profit was generated for every dollar of assets it reports. Vaxxinity has a negative utilization of assets of -0.48 %, losing $0.004834 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Vaxxinity shows how discouraging it operates for each dollar spent on its assets.Vaxxinity Ownership Allocation
Vaxxinity shows a total of 112.91 Million outstanding shares. Vaxxinity maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On January 19, 2024, Senator Rick Scott of US Senate acquired under $15k worth of Vaxxinity's common stock.Vaxxinity Profitability Analysis
Net Loss for the year was (56.93 M) with loss before overhead, payroll, taxes, and interest of (1.87 M).About Vaxxinity Valuation
Our relative valuation model uses a comparative analysis of Vaxxinity. We calculate exposure to Vaxxinity's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaxxinity's related companies.Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. Vaxxinity Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
8 Steps to conduct Vaxxinity's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vaxxinity's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vaxxinity's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vaxxinity's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vaxxinity's revenue streams: Identify Vaxxinity's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vaxxinity's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vaxxinity's growth potential: Evaluate Vaxxinity's management, business model, and growth potential.
- Determine Vaxxinity's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vaxxinity's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Vaxxinity Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 126.5 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Vaxxinity Pink Sheet
If you are still planning to invest in Vaxxinity check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaxxinity's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |